Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Anti-FLT3 CAR-T in R/R AML
NCT06786533Phase 1Recruiting
- Sponsor
- Hemogenyx Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HG-CT-1 in acute myeloid leukemia (AML) (4 arms), sponsored by Hemogenyx Pharmaceuticals. Primary endpoint: Dose Limiting Toxicity at Day 28. Started Jan 2025; status: recruiting.
02
Drugs
HG-CT-1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06786533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786533.